2016/07/26 by Robert L. Rosenfield, David A. Ehrmann · 4 citations
Medicine · #Ovarian cancer diagnosis and treatment #Ovarian function and disorders #Reproductive Biology and Fertility
paper · pdf · doi:10.1210/er.2015-1104
openalex publication_date 2016/07/26 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/02
Polycystic ovary syndrome (PCOS) was hypothesized to result from functional ovarian hyperandrogenism (FOH) due to dysregulation of androgen secretion in 1989 -1995. Subsequent studies have supported and amplified this hypothesis. When defined as otherwise unexplained hyperandrogenic oligoanovulation, two-thirds of PCOS cases have functionally typical FOH, characterized by 17-hydroxyprogesterone hyperresponsiveness to gonadotropin stimulation. Two-thirds of the remaining PCOS have FOH detectable by testosterone elevation after suppression of adrenal androgen production. About 3% of PCOS have a related isolated functional adrenal hyperandrogenism. The remaining PCOS cases are mild and lack evidence of steroid secretory abnormalities; most of these are obese, which we postulate to account for their atypical PCOS. Approximately half of normal women with polycystic ovarian morphology (PCOM) have subclinical FOH-related steroidogenic defects. Theca cells from polycystic ovaries of classic PCOS patients in long-term culture have an intrinsic steroidogenic dysregulation that can account for the steroidogenic abnormalities typical of FOH. These cells overexpress most steroidogenic enzymes, particularly cytochrome P450c17. Overexpression of a protein identified by genome-wide association screening, differentially expressed in normal and neoplastic development 1A.V2, in normal theca cells has reproduced this PCOS phenotype in vitro. A metabolic syndrome of obesity-related and/or intrinsic insulin resistance occurs in about half of PCOS patients, and the compensatory hyperinsulinism has tissue-selective effects, which include aggravation of hyperandrogenism. PCOS seems to arise as a complex trait that results from the interaction of diverse genetic and environmental factors. Heritable factors include PCOM, hyperandrogenemia, insulin resistance, and insulin secretory defects. Environmental factors include prenatal androgen exposure and poor fetal growth, whereas acquired obesity is a major postnatal factor. The variety of pathways involved and lack of a common thread attests to the multifactorial nature and heterogeneity of the syndrome. Further research into the fundamental basis of the disorder will be necessary to optimally correct androgen levels, ovulation, and metabolic homeostasis. (Endocrine Reviews 37: 467-520, 2016) I. Historical Perspective II. Definition of Polycystic Ovary Syndrome (PCOS) III. Normal Androgen Physiology A. Biochemical and molecular overview of steroidogenesis B. Regulation of ovarian function 1. Regulation of gonadotropin secretion 2. Regulation of ovarian steroidogenesis a. Homologous desensitization to LH b. Modulation of LH action 3. Folliculogenesis and its regulation C. Regulation of adrenal androgen production D. Regulation of peripheral androgen production E. Summary of normal androgen physiology IV. Source of Androgen Excess in PCOS A. Testing to determine the source of androgen in PCOS B. Functional Ovarian Hyperandrogenism (FOH) in PCOS 1. Spectrum of ovarian androgenic function in PCOS: Typical and atypical FOH 2. Spectrum of ovarian androgenic function in asymptomatic women with polycystic ovarian morphology (PCOM)